Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | BAX | Q07812 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2168004 | 0.89 | DPP4 (0.41) | LTA4HTSHRKMT2AKDM4EGLA | |
| SCHEMBL1283546 | 0.86 | HTR2A (0.40) | KMT2AKDM4EMAPTHTTSLC6A2 | |
| SCHEMBL1451754 | 0.86 | HTR2A (0.41) | KMT2AMAPTLMNAHTTSLC6A4 | |
| SCHEMBL6305659 | 0.86 | MAPK14 (0.32) | KMT2AKDM4EGLAMAPTLMNA | |
| SCHEMBL19732700 | 0.76 | ALDH1A1 (0.40) | KMT2AMAPTGAAALDH1A1HPGD | |
| SCHEMBL7753169 | 0.76 | IDO1 (0.44) | TSHRKDM4EMAPTLMNAHTT | |
| SCHEMBL148270 | 0.76 | IDO1 (0.44) | TSHRKDM4EMAPTLMNAHTT | |
| SCHEMBL536544 | 0.74 | LTA4H (0.58) | LTA4HTSHRKMT2AKDM4EGLA | |
| SCHEMBL5934194 | 0.73 | MAPT (0.44) | LTA4HTSHRMAPTLMNASLC6A2 | |
| SCHEMBL8123676 | 0.73 | RHEB (0.48) | KMT2AMAPTDPP4SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2243805-B1 | ANTHRAPYRIDONE COMPOUND OR SALT THEREOF, MAGENTA INK COMPOSITION CONTAINING THE ANTHRAPYRIDONE COMPOUND, AND COLORED BODY | NIPPON KAYAKU KK (JP) | 2014-11-26 | — | — | EP | disclosed |
| EP-1608369-B1 | USE OF ORGANIC COMPOUNDS FOR IMMUNOPOTENTIATION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2013-06-26 | — | — | EP | disclosed |
| EP-2258365-B1 | USE OF ORGANIC COMPOUNDS FOR IMMUNOPOTENTIATION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2013-05-29 | — | — | EP | disclosed |
| US-8350995-B2 | Optical film, production method of optical film, optically-compensatory film, polarizing plate and liquid crystal display device | FUJIFILM CORPORATION (JP) | 2013-01-08 | — | — | US | disclosed |
| US-20120276141-A1 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | SRIVASTAVA INDRESH K (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120244182-A1 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| EP-1594524-B1 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2012-08-15 | — | — | EP | disclosed |
| US-8197819-B2 | Exposure of epitopes on envelop protein; complex of polypeptide and antigen; induce immunology response | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-8193185-B2 | Administering a tryptanthrin compound, e.g., 8-nitroindolo[2,1-b]quinazoline-6,12-dione, to potentiate the immune response to an antigen; immunostimulants; small molecule immune potentiators; immunotherapy for infectious diseases; anticarcinogenic agents; vaccine adjuvant compositions and kits | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| CN-101300307-B | Polymer film, method for producing polymer film, optical film and polarizing plate, and liquid crystal display device using the polarizing plate | FUJI PHOTO FILM CO LTD | 2012-05-09 | — | — | CN | disclosed |
| WO-1995021815-A1 | CYCLOBUTANE DERIVATIVES AND THEIR USE AS INHIBITORS OF PROTEIN FARNESYLTRANSFERASE AND SQUALENE SYNTHASE | ABBOTT LABORATORIES (US) | 1995-08-17 | — | — | WO | disclosed |
| US-5441955-A | Tuberculosis | PATHOGENESIS CORPORATION (US) | 1995-08-15 | — | — | US | disclosed |
| WO-1995013807-A1 | INDOLO[2,1-b]QUINAZOLINE-6,12-DIONE ANTIBACTERIAL COMPOUNDS AND METHODS OF USE THEREOF | PATHOGENESIS CORPORATION (US) | 1995-05-26 | — | — | WO | disclosed |
| US-5399558-A | Isoflavonoid antibacterial compounds, compositions and use | PATHOGENESIS CORPORATION (US) | 1995-03-21 | — | — | US | disclosed |
| US-5391806-A | A storage stable chromogens as color-developing agent or stabilizers | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1995-02-21 | — | — | US | disclosed |
| EP-0621273-A1 | NOVEL SULFONIC ACIDE DERIVATIVE AND MEDICINAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 1994-10-26 | — | — | EP | disclosed |
| US-5306688-A | Color-forming, electron donating compound and electron accepting compound; storage stability of uncolored portion | MITSUI TOATSU CHEMICALS, INC. (JP) | 1994-04-26 | — | — | US | disclosed |
| US-5270281-A | Chromogenic compound | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1993-12-14 | — | — | US | disclosed |
| EP-0534257-A1 | Salicylic acid derivatives, the process for preparing the same and the heat-sensitive recording materials comprising thereof | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1993-03-31 | — | — | EP | disclosed |
| EP-0524419-A1 | Heat-sensitive recording materials and phenol compounds | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1993-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120244182-A1 | USE OF TRYPTANTHRIN COMPOUNDS FOR IMMUNE POTENTIATION | TPSG1, TPSB2, TPSAB1 | LTA4H 182/4885TSHR 3918/4885KMT2A 2442/4885 |
| US-20120276141-A1 | ENV POLYPEPTIDE COMPLEXES AND METHODS OF USE | CD4, CD74, HAVCR2 | LTA4H 1489/4885TSHR 3875/4885KMT2A 4731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.